By the same authors

From the same journal

From the same journal

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

Research output: Contribution to journalLiterature review

Standard

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. / Wilby, J; Kainth, A; Hawkins, N; Epstein, D; McIntosh, H; McDaid, C; Mason, A; Golder, S; O'Meara, S; Sculpher, M; Drummond, M; Forbes, C.

In: Health technology assessment, Vol. 9, No. 15, 05.2005.

Research output: Contribution to journalLiterature review

Harvard

Wilby, J, Kainth, A, Hawkins, N, Epstein, D, McIntosh, H, McDaid, C, Mason, A, Golder, S, O'Meara, S, Sculpher, M, Drummond, M & Forbes, C 2005, 'Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation', Health technology assessment, vol. 9, no. 15.

APA

Wilby, J., Kainth, A., Hawkins, N., Epstein, D., McIntosh, H., McDaid, C., ... Forbes, C. (2005). Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. Health technology assessment, 9(15).

Vancouver

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C et al. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. Health technology assessment. 2005 May;9(15).

Author

Wilby, J ; Kainth, A ; Hawkins, N ; Epstein, D ; McIntosh, H ; McDaid, C ; Mason, A ; Golder, S ; O'Meara, S ; Sculpher, M ; Drummond, M ; Forbes, C. / Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation. In: Health technology assessment. 2005 ; Vol. 9, No. 15.

Bibtex - Download

@article{9f7e9dc6f52f4a65ab43dd18a5467fb8,
title = "Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation",
abstract = "The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.",
keywords = "ADD-ON THERAPY, QUALITY-OF-LIFE, REFRACTORY PARTIAL EPILEPSY, NEWLY-DIAGNOSED EPILEPSY, COMPLEX PARTIAL SEIZURES, PLACEBO-CONTROLLED TRIAL, PARTIAL-ONSET SEIZURES, RESISTANT PARTIAL EPILEPSY, GAMMA-VINYL-GABA, VISUAL-FIELD DEFECTS",
author = "J Wilby and A Kainth and N Hawkins and D Epstein and H McIntosh and C McDaid and A Mason and S Golder and S O'Meara and M Sculpher and M Drummond and C Forbes",
year = "2005",
month = "5",
language = "English",
volume = "9",
journal = "Health technology assessment",
issn = "1366-5278",
publisher = "NHS National Institute for Health Research",
number = "15",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: A systematic review and economic evaluation

AU - Wilby, J

AU - Kainth, A

AU - Hawkins, N

AU - Epstein, D

AU - McIntosh, H

AU - McDaid, C

AU - Mason, A

AU - Golder, S

AU - O'Meara, S

AU - Sculpher, M

AU - Drummond, M

AU - Forbes, C

PY - 2005/5

Y1 - 2005/5

N2 - The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

AB - The aim of this review was to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults. For the purposes of this review newer antiepileptic drugs (AEDs) included gabapentin (GBP) (Neurontin(R), Parke-Davis), lamotrigine (LTG) (Lamictal(R), GlaxoSmithKline), levetiracetam (LEV) (Keppra(R), UCB Pharma), oxcarbazepine (OXC) (Trileptal(R), Novartis Pharmaceuticals), tiagabine (TGB) [Gabatril(R), Cephalon (UK)], topiramate (TPM) (Topomax(R), Janssen-Cilag) and vigabatrin (VGB) (Sabril(R), Hoechst Marion Roussel). A concurrent review was performed by the West Midlands Health Technology Assessment Collaboration (WMHTAC), Birmingham, to examine the clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in children.

KW - ADD-ON THERAPY

KW - QUALITY-OF-LIFE

KW - REFRACTORY PARTIAL EPILEPSY

KW - NEWLY-DIAGNOSED EPILEPSY

KW - COMPLEX PARTIAL SEIZURES

KW - PLACEBO-CONTROLLED TRIAL

KW - PARTIAL-ONSET SEIZURES

KW - RESISTANT PARTIAL EPILEPSY

KW - GAMMA-VINYL-GABA

KW - VISUAL-FIELD DEFECTS

M3 - Literature review

VL - 9

JO - Health technology assessment

JF - Health technology assessment

SN - 1366-5278

IS - 15

ER -